Dr. Den Discusses the Future of Prostate Cancer Research

Robert B. Den, MD
Published: Wednesday, Apr 25, 2018



Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.

The field of prostate cancer has gone through an explosion within the last 5 to 10 years with the FDA approvals of multiple agents. These agents have shown activity in late-stage disease, and subsequent trials have begun to show activity in earlier-stage disease, Den says. This has garnered a lot of hope for the treatment of patients with prostate cancer, as these agents are now proven to be active earlier in the disease state, and may increase survival.

Den says that these advances have led more people to become actively involved in prostate cancer research. DNA-damaging agents, such as PARP inhibitors and DNA-PK inhibitors, are being investigated, and phase II trials have shown that selecting patients by mutation may ensure benefit. This is a new area of prostate cancer research that will soon be manifested in clinical benefit for patients, Den concludes.


Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.

The field of prostate cancer has gone through an explosion within the last 5 to 10 years with the FDA approvals of multiple agents. These agents have shown activity in late-stage disease, and subsequent trials have begun to show activity in earlier-stage disease, Den says. This has garnered a lot of hope for the treatment of patients with prostate cancer, as these agents are now proven to be active earlier in the disease state, and may increase survival.

Den says that these advances have led more people to become actively involved in prostate cancer research. DNA-damaging agents, such as PARP inhibitors and DNA-PK inhibitors, are being investigated, and phase II trials have shown that selecting patients by mutation may ensure benefit. This is a new area of prostate cancer research that will soon be manifested in clinical benefit for patients, Den concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x